Last reviewed · How we verify
recombinant alpha-galactosidase A
At a glance
| Generic name | recombinant alpha-galactosidase A |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease (PHASE3)
- A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease (PHASE2, PHASE3)
- Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (PHASE2, PHASE3)
- Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease (PHASE3)
- Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients (PHASE3)
- Extension Study of PRX-102 for up to 60 Months (PHASE1, PHASE2)
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (PHASE3)
- Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |